Cognitive control Training as an adjunct to behavioral activation therapy in the treatment of depression

Major depressive disorder (MDD) is characterized by reduced activation of the dorsolateral prefrontal cortex (DLPFC), a brain region involved in both emotion regulation and basic cognitive control processes. Recent studies have indicated that computerized interventions designed to activate the DLPFC can reduce depressive symptoms. The current study was a randomized controlled trial which extends this research to test whether one such program, called Cognitive Control Training (CCT), enhances depression treatment outcomes when used in adjunct to brief behavioral activation therapy for depression (BATD), an empirically-supported outpatient intervention. This study also explored whether the effects of BATD + CCT treatment on depression were mediated by changes in rumination and cognitive control. In a sample of thirty-four adults diagnosed with MDD, participants were randomly assigned to complete four sessions of either computerized CCT or a non-active computerized control task, concurrently with four sessions of BATD. Completion of the assigned computerized task took place immediately before each of the four BATD therapy sessions. Depression symptoms and proposed treatment mediators were assessed at baseline, mid-treatment, post-treatment, and four-week follow-up visits. I hypothesized that compared to the control group, participants receiving adjunctive CCT would demonstrate significantly reduced depressive symptoms. I also hypothesized that these effects would be mediated by changes in inhibitory control and set-shifting performance in the context of negative emotional material, as well as by changes in ruminative brooding. Results did not support these hypotheses. Depressive symptoms were reduced over time in both treatment conditions, with no significant difference between treatment conditions. Assignment to CCT was not associated with changes in the proposed mediators. Furthermore, exploratory analyses found minimal evidence that performance on inhibitory control and set-shifting tasks were related to baseline clinical characteristics (such as depression severity, rumination, or anxiety symptoms) or treatment outcomes. The results of this study support the potential for BATD as a brief, low-cost, flexible intervention for the treatment of depression and further show that CCT administered in adjunct to a 4-session BATD program does not add clinical benefit in the treatment of depression. This study and other recent research suggest that the effects of CCT may not be as robust as previously indicated, highlighting the need for continued investigation of the conditions under which CCT may be effective

Treatment Outcome and Predictors of Internet Guided Self-Help for Obsessive-Compulsive Disorder

Internet-guided self-help (iGSH) has amassed significant empirical support for a variety of psychiatric conditions; however, it is not known who responds best to these treatments. This open trial examined the clinical outcomes and predictors of a 17-week iGSH program for obsessive-compulsive disorder (OCD). Therapist support was provided either in person or by phone 9 times for an average of 13 minutes per session. Twenty-four patients initiated treatment, and 17 of these (70.8%) completed. Results of the intent-to-treat sample indicated statistically significant improvements at posttreatment with large treatment effects for OCD symptoms as assessed by the Yale Brown Obsessive-Compulsive Scale (d = 0.87), and small to moderate improvements in depression (d = 0.19), functioning (d = 0.53), and quality of life (d = -0.18). These outcomes were largely maintained over a 6-month follow-up. Readiness to reduce avoidance of OCD triggers and attendance to therapist sessions were moderately associated with posttreatment response, and correctly classified the responder status (defined as clinically significant change) of nearly 9 out of 10 patients at posttreatment. These same variables did not predict responder status at 6-month follow-up. These results lend further empirical support to iGSH as a treatment for OCD and provide direction on the development of predictor models to identify patients who are and are not likely to acutely respond to iGSH

The relationship between self-reported and objective neuropsychological impairments in patients with hoarding disorder

Although hoarding disorder (HD) is characterized by self- and clinician-reported difficulties with cognitive functioning, studies of neuropsychological performance have yielded little evidence of consistent, clinical-level cognitive impairments. The aim of this study was to quantify this inconsistency and to examine whether this pattern is unique to HD. Fifty-three adults (20 with HD, 19 with obsessive compulsive disorder (OCD) and minimal hoarding symptoms, and 14 with OCD and a high degree of hoarding symptoms (OCD-H)) completed self-report and objective neuropsychological tests of inhibition, attention, and memory. The three groups differed significantly on self-reported attention and memory deficits, with the HD group reporting greater difficulties. However, the groups performed comparably on objective neuropsychological tests of inhibition, attention, immediate and delayed nonverbal memory, and immediate verbal memory. The OCD-H group demonstrated a greater rate of impairment on a test of delayed verbal memory. The HD group was characterized by lower concordance rates between self-report and objective memory impairment. The groups did not differ significantly in concordance rates for self-report and objective measures of attention and inhibition. Understanding the discrepancy between self-report and objective neuropsychological measures may help to better characterize the role of cognitive processes in HD

Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.

BackgroundMore data are needed to guide next-step interventions for panic disorder refractory to initial intervention.MethodThis 24-week randomized clinical trial (RCT) enrolled 46 patients with DSM-IV-defined panic disorder from November 2000 to April 2005 and consisted of 3 phases. Patients who failed to meet remission criteria were eligible for randomization in the next treatment phase. Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission). Phase 2 was a 6-week double-blind RCT of (1) increased-dose selective serotonin reuptake inhibitor (SSRI) versus (2) continued SSRI plus placebo. Phase 3 was a 12-week RCT of added cognitive-behavioral therapy (CBT) compared to "medication optimization" with SSRI plus clonazepam. Primary endpoints were remission and change in Panic Disorder Severity Scale (PDSS) score in the intent-to-treat sample in each phase.ResultsIn phase 1, 20.5% (8/39) of the patients achieved remission, and only baseline severity predicted endpoint PDSS score (beta [SE] = 1.04 [0.15], t = 6.76, P < .001). In phase 2, increasing the SSRI dose did not result in greater improvement or remission rates (placebo 15% [n = 2] vs increased dose 9% [n = 1]: Fisher exact test P = NS). In phase 3, remission was minimal (medication optimization = 11% [n = 1]; CBT = 10% [n = 1]), with a lack of group difference in PDSS score reduction (t(17) = 0.51, P > .60) consistent with a small effect size (d = 0.24).ConclusionsAlthough power was limited and larger studies are needed, we failed to find evidence for greater benefit of increased SSRI dose versus continuation of current dose for panic disorder symptomatic after 6 weeks at moderate dose. Further, augmentation with CBT or medication optimization with clonazepam augmentation in nonremitted panic after 12 weeks of an SSRI did not differ, suggesting that both are reasonable next-step options. However, low overall remission rates in this comorbid refractory population suggest that better predictors of response to specific treatments over time and additional interventions are needed.Trial registrationclinicaltrials.gov Identifier: NCT00118417

Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.

BackgroundMore data are needed to guide next-step interventions for panic disorder refractory to initial intervention.MethodThis 24-week randomized clinical trial (RCT) enrolled 46 patients with DSM-IV-defined panic disorder from November 2000 to April 2005 and consisted of 3 phases. Patients who failed to meet remission criteria were eligible for randomization in the next treatment phase. Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission). Phase 2 was a 6-week double-blind RCT of (1) increased-dose selective serotonin reuptake inhibitor (SSRI) versus (2) continued SSRI plus placebo. Phase 3 was a 12-week RCT of added cognitive-behavioral therapy (CBT) compared to "medication optimization" with SSRI plus clonazepam. Primary endpoints were remission and change in Panic Disorder Severity Scale (PDSS) score in the intent-to-treat sample in each phase.ResultsIn phase 1, 20.5% (8/39) of the patients achieved remission, and only baseline severity predicted endpoint PDSS score (beta [SE] = 1.04 [0.15], t = 6.76, P < .001). In phase 2, increasing the SSRI dose did not result in greater improvement or remission rates (placebo 15% [n = 2] vs increased dose 9% [n = 1]: Fisher exact test P = NS). In phase 3, remission was minimal (medication optimization = 11% [n = 1]; CBT = 10% [n = 1]), with a lack of group difference in PDSS score reduction (t(17) = 0.51, P > .60) consistent with a small effect size (d = 0.24).ConclusionsAlthough power was limited and larger studies are needed, we failed to find evidence for greater benefit of increased SSRI dose versus continuation of current dose for panic disorder symptomatic after 6 weeks at moderate dose. Further, augmentation with CBT or medication optimization with clonazepam augmentation in nonremitted panic after 12 weeks of an SSRI did not differ, suggesting that both are reasonable next-step options. However, low overall remission rates in this comorbid refractory population suggest that better predictors of response to specific treatments over time and additional interventions are needed.Trial registrationclinicaltrials.gov Identifier: NCT00118417